---
title: "Xarelto (rivaroxaban), all indications: Pharmacology questions"
description: "Pharmacology questions on Xarelto (rivaroxaban) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: What type of drug is Xarelto? How does Xarelto work (mechanism of action)? How long does Xarelto stay in your system (half-life)? How is Xarelto metabolized and eliminated? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/xarelto/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xarelto (rivaroxaban), all indications: Pharmacology questions

Manufacturer: Janssen Pharmaceuticals, Inc.  
Prescribing information: [Xarelto](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf)  
Indication pages: [Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation)

## Mechanism

<a id="xarelto-drug-class"></a>

### What type of drug is Xarelto?

> “XARELTO is a factor Xa inhibitor indicated:”

Source: [XARELTO: Prescribing information, page 1, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=1)

> “Rivaroxaban, a factor Xa (FXa) inhibitor, is the active ingredient in XARELTO<sup>®</sup> Tablets 
> and XARELTO<sup>®</sup> for oral suspension”

Source: [XARELTO: Prescribing information, page 12, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=12)

<a id="xarelto-mechanism"></a>

### How does Xarelto work (mechanism of action)?

> “XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as 
> Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase 
> activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly 
> inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban 
> decreases thrombin generation.”

Source: [XARELTO: Prescribing information, page 12, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=12)

## Pharmacokinetics

<a id="xarelto-half-life"></a>

### How long does Xarelto stay in your system (half-life)?

> “Rivaroxaban is a low-clearance drug, with a systemic clearance of approximately 
> 10 L/hr in healthy volunteers following intravenous administration. The terminal 
> elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 
> 45 years.”

Source: [XARELTO: Prescribing information, page 13, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=13)

> “The terminal elimination half-life is 11 to 13 hours in the elderly subjects aged 60 to 
> 76 years”

Source: [XARELTO: Prescribing information, page 13, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=13)

Note: The label gives the half-life in healthy subjects aged 20 to 45 years and in elderly subjects aged 60 to 76 years.

<a id="xarelto-metabolism"></a>

### How is Xarelto metabolized and eliminated?

> “Approximately 51% of an orally administered [<sup>14</sup>C]-rivaroxaban dose was 
> recovered as inactive metabolites in urine (30%) and feces (21%). Oxidative 
> degradation catalyzed by CYP3A4/5 and CYP2J2 and hydrolysis are the major sites 
> of biotransformation. Unchanged rivaroxaban was the predominant moiety in 
> plasma with no major or active circulating metabolites.”

Source: [XARELTO: Prescribing information, page 12, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=12)

> “In a Phase 1 study, following the administration of [<sup>14</sup>C]-rivaroxaban, approximately one-
> third (36%) was recovered as unchanged drug in the urine and 7% was recovered 
> as unchanged drug in feces. Unchanged drug is excreted into urine, mainly via active”

Source: [XARELTO: Prescribing information, page 12, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=12)

> “tubular secretion and to a lesser extent via glomerular filtration (approximate 5:1 ratio).”

Source: [XARELTO: Prescribing information, page 13, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=13)

Note: The second and third passages are one sentence that continues from page 12 to page 13 of the Prescribing Information.

## Components

<a id="xarelto-inactive-ingredients"></a>

### What are the inactive ingredients in Xarelto tablets?

> “Each XARELTO tablet contains 2.5 mg, 10 mg, 15 mg, or 20 mg of rivaroxaban. The 
> inactive ingredients of XARELTO are: croscarmellose sodium, hypromellose, 
> lactose monohydrate, magnesium stearate, microcrystalline cellulose, and 
> sodium lauryl sulfate. Additionally, the proprietary film coating mixture used for 
> XARELTO 2.5 mg is Opadry<sup>®</sup> Light Yellow, containing ferric oxide yellow, 
> hypromellose, polyethylene glycol 3350, and titanium dioxide, and for XARELTO 
> 10 mg tablets is Opadry<sup>®</sup> Pink and for XARELTO 15 mg tablets is Opadry<sup>®</sup> Red, 
> both containing ferric oxide red, hypromellose, polyethylene glycol 3350, and 
> titanium dioxide, and for XARELTO 20 mg tablets is Opadry<sup>®</sup> II Dark Red, 
> containing ferric oxide red, polyethylene glycol 3350, polyvinyl alcohol (partially 
> hydrolyzed), talc, and titanium dioxide.”

Source: [XARELTO: Prescribing information, page 12, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=12)

## Related pages
- [Medical information: Xarelto (rivaroxaban): All indications](https://www.evicenter.com/medical-information/xarelto)
- [Indication](https://www.evicenter.com/medical-information/xarelto/indication)
- [Safety](https://www.evicenter.com/medical-information/xarelto/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xarelto/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xarelto/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xarelto/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/xarelto/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/xarelto/access-and-coverage)
